Dyadic International (DYAI) Profit After Tax (2018 - 2026)
Dyadic International (DYAI) posted Profit After Tax of -$2.0 million for Q1 2026, down 24.72% sequentially from -$1.6 million in Q4 2025, and up 3.6% YoY from -$1.9 million in Q1 2025.
Dyadic International (DYAI) Profit After Tax (2018 - 2026) Analysis & Trends
Dyadic International has reported Profit After Tax for 9 years, with the latest figure at -$2.0 million in Q1 2026.
- Quarterly Profit After Tax rose 3.6% year-over-year to -$2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.3 million (down 25.13% YoY) and the FY2025 annual result came in at -$7.4 million, down 26.78% from the prior year.
- Profit After Tax fell to -$2.0 million in Q1 2026 per DYAI's latest filing, from -$1.6 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$203460.0 in Q3 2024 and troughed at -$3.3 million in Q2 2022.
- A 5-year average of -$1.9 million and a median of -$2.0 million in 2025 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax surged 87.4% in 2024, then tumbled 871.2% in 2025.
- Over 5 years, Profit After Tax stood at -$2.1 million in 2022, then increased by 3.48% to -$2.1 million in 2023, then grew by 25.14% to -$1.6 million in 2024, then dropped by 1.06% to -$1.6 million in 2025, then decreased by 24.72% to -$2.0 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$2.0 million, -$1.6 million, and -$2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | -1.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.95 Mn |
| Dec 31, 2025 | -1.57 Mn |
| Sep 30, 2025 | -1.98 Mn |
| Jun 30, 2025 | -1.79 Mn |
| Mar 31, 2025 | -2.03 Mn |
| Dec 31, 2024 | -1.55 Mn |
| Sep 30, 2024 | -203,460.00 |
| Jun 30, 2024 | -2.05 Mn |
| Mar 31, 2024 | -2.01 Mn |
| Dec 31, 2023 | -2.07 Mn |
| Sep 30, 2023 | -1.61 Mn |
| Jun 30, 2023 | -2.15 Mn |
| Mar 31, 2023 | -956,444.00 |
| Dec 31, 2022 | -2.15 Mn |
| Sep 30, 2022 | -1.81 Mn |
| Jun 30, 2022 | -3.29 Mn |
| Mar 31, 2022 | -2.49 Mn |
| Dec 31, 2021 | -4.21 Mn |
| Sep 30, 2021 | -1.72 Mn |
| Jun 30, 2021 | -3.85 Mn |